A team of researchers from the UCLA have recently discovered a new process in the growth of late-stage and the small cell cancer of the lung and prostate. As per their study, these shared molecular mechanism is expected to lead to the development of drugs in order to treat not only the lung and prostate cancers but also the cell cancers of any other organ in the body.
As per the research study, the lung and prostate cells have quite different patterns of gene expression when they are in a healthy condition. However, when they transform into small cell cancers, they almost have identical patterns. The research study further states that the small cell tumors, even if they are of different type evolve similarly. This is the case, even if the tumors come from different organs.
The research study, which is being managed by Dr. Owen Witte, who is the founding director of the Edythe Broad Center of Stem Cell Research and Regenerative Medicine and ULA Eli and the professor of immunology, microbiology, and molecule genetics, has been recently published in the Journal Science. Dr. Owen Witte has collaborated with some more scientists from the UCLA Josson Comprehensive Cancer Center and the UCLS’s Crump Institute for Molecular Imaging.
The research team has further established that for the small cell neuroendocrine carcinomas to further develop into the prostate, two tumor suppressors genes, which are RB1 and TP53, which are quite known for their capacity of protecting the normal cell to get transformed into cancer cells. This has to be inactivated simultaneously after the PARCB was introduced. Some of the additional tests have given a confirmation that there are some similarities among the small cell prostate cancer cells from human and PARCB-SCNC cells.